Jefferies Initiates a Buy Rating on Dimension Therapeutics Inc

By Ryan Adsit

In a report released yesterday, Gena Wang from Jefferies initiated coverage with a Buy rating on Dimension Therapeutics Inc (NASDAQ: DMTX) and a price target of $12. The company’s shares closed yesterday at $4.55.

Wang noted:

“DTMX 3Q16 earnings release highlighted clinical progress including initial DTX101 Ph1/2 data expected in Jan ’17 in hemoB (n=5+) and on-track DTX301 IND filing and Ph1/2 initiation by YE16. Selection of DTX101 2nd dose at higher end of guided range may suggest good safety profile with modest FIX activity in the 1st cohort.”

According to TipRanks.com, Wang is ranked 0 out of 5 stars with an average return of -25.6% and a 30.8% success rate. Wang covers the Healthcare sector, focusing on stocks such as Cascadian Therapeutics, Atara Biotherapeutics, and Intellia Therapeutics.

Dimension Therapeutics Inc has an analyst consensus of Moderate Buy.

The company has a one year high of $15.55 and a one year low of $0. Currently, Dimension Therapeutics Inc has an average volume of 76.02K.

Dimension Therapeutics, Inc. engages in the provision of medical development. Its activities include discoveries and development of therapeutic products for people living with rare diseases associated wit the liver and caused by genetic mutations. The company was founded by Ben Auspitz on October 2013, and is headquartered in Cambridge, MA.